<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77368">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098343</url>
  </required_header>
  <id_info>
    <org_study_id>APR-407</org_study_id>
    <nct_id>NCT02098343</nct_id>
  </id_info>
  <brief_title>p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246</brief_title>
  <official_title>PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aprea Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aprea Therapeutics AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to make a preliminary assessment of the efficacy of a combined
      APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy
      regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian
      cancer (HGSOC) with mutated p53. In addition, the study aims to assess the safety profile of
      the combined APR-246 and carboplatin/PLD chemotherapy regimen compared with carboplatin/PLD
      chemotherapy regimen alone, to evaluate potential biomarkers, and to assess the biological
      activity in tumor and surrogate tissues. The trial will enroll up to a maximum of 400
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Dose-limiting toxicities (DLT) (see Description) of combined APR-246 and carboplatin/PLD regimen</measure>
    <time_frame>Until the end of the first treatment cycle, i.e., Day 28</time_frame>
    <description>DLT: Hematological and non-hematological toxicities according to grade/days stated in the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Safety Profile (see Description) of combined APR-246 and carboplatin/PLD regimen</measure>
    <time_frame>Until 30 days after the last administration of study treatment to the patient</time_frame>
    <description>Safety Analysis: Adverse events (AEs) will be summarized by body system, preferred term, severity, and relationship to treatment. Serious adverse events, deaths, and AEs leading to early discontinuation of study drug will be summarized. Laboratory parameters will be summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Maximum observed plasma concentration (Cmax) of APR-246</measure>
    <time_frame>Until Day 5 in cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Area under the plasma concentration-time curve (AUC) of APR-246</measure>
    <time_frame>Until Day 5 in cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Progression Free Survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time frame from registration to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Response Rate (RR)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Safety Profile (see Description) of combined APR-246 and carboplatin/PLD regimen or the carboplatin/PLD regimen alone</measure>
    <time_frame>Until 30 days after the last administration of study treatment to the patient.</time_frame>
    <description>Safety Analysis: Adverse events will be summarized by body system, preferred term, severity, and relationship to treatment. Serious adverse events, deaths, and AEs leading to early discontinuation of study drug will be summarized. Laboratory parameters will be summarized.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53</condition>
  <arm_group>
    <arm_group_label>Phase Ib. APR-246 + Carboplatin/PLD.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of APR-246.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Arm A. APR-246 + Carboplatin/PLD.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Arm B. Carboplatin/PLD.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APR-246</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Phase Ib. APR-246 + Carboplatin/PLD.</arm_group_label>
    <arm_group_label>Phase II: Arm A. APR-246 + Carboplatin/PLD.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Phase Ib. APR-246 + Carboplatin/PLD.</arm_group_label>
    <arm_group_label>Phase II: Arm A. APR-246 + Carboplatin/PLD.</arm_group_label>
    <arm_group_label>Phase II: Arm B. Carboplatin/PLD.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical
             (IHC) staining for p53

          -  Disease Progression between 6-24 months after a first or second platinum based
             regimen

          -  At least a single measurable lesion. Phase II patients only

          -  Adequate organ function prior to registration

          -  Toxicities from previous cancer therapies must have recovered to grade 1 (defined by
             Common Terminology Criteria for Adverse Events [CTCAE] 4.0) Chronic stable grade 2
             peripheral neuropathy secondary to neurotoxicity from prior therapies may be
             considered on a case by case basis

          -  ECOG performance status of 0 to 1

        Exclusion Criteria:

          -  Prior exposure to cumulative doses of doxorubicin &gt;400 mg/m2 or epirubicin &gt;720 mg/m2

          -  History of allergic reactions to carboplatin, platinum containing compounds or
             mannitol and/or hypersensitivity to PLD or to any of the excipients

          -  Unable to undergo imaging by either CT scan or MRI

          -  Evidence of any other medical conditions (such as psychiatric illness, infectious
             diseases, neurological conditions, physical examination or laboratory findings) that
             may interfere with the planned treatment, affect patient compliance or place the
             patient at high risk from treatment related complications

          -  Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or
             carcinoma in situ)

          -  Is taking concurrent (or within 4 week prior to registration) chemotherapy,
             immunotherapy, radiotherapy, or any ancillary therapy that is considered to be
             investigational (i.e., used for non-approved indications(s) and in the context of a
             research investigation). Supportive care measures are allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Green, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinating Investigator. Clatterbridge Centre for Oncology, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikael von Euler, MD PhD FFPM</last_name>
    <email>Mikael.vonEuler@aprea.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>MA 02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>TX 75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>TX 77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Antwerpen</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medische oncologie, Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leuven University Hospitals</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital des Diaconesses (Site Reuilly)</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia, Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Research Centre, The University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College London, Hammersmith Hospital Campus</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aprea.com</url>
    <description>Aprea AB's website (Sponsor)</description>
  </link>
  <reference>
    <citation>Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.</citation>
    <PMID>22965953</PMID>
  </reference>
  <reference>
    <citation>Deneberg S, Cherif H, Lazarevic V, Andersson PO, von Euler M, Juliusson G, Lehmann S. An open-label phase I dose-finding study of APR-246 in hematological malignancies. Blood Cancer J. 2016 Jul 15;6(7):e447. doi: 10.1038/bcj.2016.60.</citation>
    <PMID>27421096</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>March 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Ovarian carcinoma</keyword>
  <keyword>High Grade Serous Ovarian Cancer</keyword>
  <keyword>Recurrent Cancer</keyword>
  <keyword>Resistant Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
